Yuri Ito

Yuri Ito

Auto-generated profile, based on publicly available information

Yuri Ito

Department of Medical Statistics, Research & Development Center, Osaka Medical and Pharmaceutical University

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2021 in Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
Kota KatanodaKota Katanoda
Kota Katanoda
MHMegumi Hori
Megumi Hori
ESEiko Saito
Eiko Saito
ASAkiko Shibata
Akiko Shibata
YIYuri Ito
Yuri Ito
TMTomohiro Matsuda
Tomohiro Matsuda
Background: Unlike many North American and European countries, Japan has observed a continuous increase in cancer incidence over the last few decades. We examined the most recent trends in population-based cancer incidence and mortality in Japan.Methods: National cancer mortality data between 1958 and 2018 were obtained from published vital statistics. Cancer incidence data between 1985 and 2015 were obtained from high-quality population-based cancer registries maintained by three prefectures (Yamagata, Fukui, and Nagasaki). Trends in age-standardized rates (ASR) were examined using Joinpoint regression analysis.Results: For males, all-cancer incidence increased between 1985 and 1996 (annual percent change (APC): +1.1% [95% confidence interval: 0.7, 1.5]), increased again in 2000-2010 (+1.3% [0.9, 1.8]), and then decreased until 2015 (-1.4% [-2.5, -0.3]). For females, all-cancer incidence increased until 2010 (+0.8% [0.6, 0.9] in 1985-2004, +2.4% [1.3, 3.4] in 2004-2010), and stabilized thereafter until 2015. The post-2000 increase was mainly attributable to prostate in males and breast in females, which slowed or levelled during the first decade of the 2000s. After a sustained increase, all-cancer mortality for males decreased in 1996-2013 (-1.6% [-1.6, -1.5]) and accelerated thereafter until 2018 (-2.5% [-2.9, -2.0]). All-cancer mortality for females decreased intermittently throughout the observation period, with the most recent APC of -1.0% [-1.1, -0.9] in 2003-2018. The recent decreases in mortality in both sexes, and in incidence in males, were mainly attributable to stomach, liver and male lung.Conclusion: The ASR of all-cancer incidence began decreasing significantly in males and levelled off in females in 2010.

26 December 2017 in Cancer Science
Verified
Journal Article
Open access
KNKayo Nakata
Kayo Nakata
YIYuri Ito
Yuri Ito
WMWinnie Magadi
Winnie Magadi
ABAudrey Bonaventure
Audrey Bonaventure
CSCharles A. Stiller
Charles A. Stiller
BRBernard Rachet
Bernard Rachet
The present study aimed to compare cancer incidence and trends in survival for children diagnosed in Japan and England, using population‐based cancer registry data. The analysis was based on 5192 children with cancer (age 0‐14 years) from 6 prefectural cancer registries in Japan and 21 295 children diagnosed in England during 1993‐2010. Differences in incidence rates between the 2 countries were measured with Poisson regression models. Overall survival was estimated using the Kaplan–Meier method. Incidence rates for Hodgkin lymphoma, renal tumors and Ewing sarcomas in England were more than twice as high as those in Japan. Incidence of germ cell tumors, hepatic tumors, neuroblastoma and acute myeloid leukemia (AML) was higher in Japan than in England. Incidence of all cancers combined decreased in Japan throughout the period 1993 to 2010, which was mainly explained by a decrease in registration of neuroblastoma in infants. For many cancers, 5‐year survival improved in both countries. The improvement in survival in chronic myeloid leukemia (CML) was particularly dramatic in both countries. However, 5‐year survival remained less than 80% in 2005‐2008 in both countries for AML, brain tumors, soft tissue sarcomas, malignant bone tumors and neuroblastoma (age 1‐14 years). There were significant differences in incidence of several cancers between countries, suggesting variation in genetic susceptibility and possibly environmental factors. The decrease in incidence for all cancers combined in Japan was related to the cessation of the national screening program for neuroblastoma. The large improvement in survival in CML coincided with the introduction of effective therapy (imatinib).

5 June 2023 in Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
MGMasahiko Gosho
Masahiko Gosho
TOTomohiro Ohigashi
Tomohiro Ohigashi
KNKengo Nagashima
Kengo Nagashima
YIYuri Ito
Yuri Ito
KMKazushi Maruo
Kazushi Maruo
Background: Logistic regression models are widely used to evaluate the association between a binary outcome and a set of covariates. However, when there are few study participants at the outcome and covariate levels, the models lead to bias of the odds ratio (OR) estimated using the maximum likelihood (ML) method. This bias is known as sparse data bias, and the estimated OR can yield impossibly large values because of data sparsity. However, this bias has been ignored in most epidemiological studies.Methods: We review several methods for reducing sparse data bias in logistic regression. The primary aim is to evaluate the Bayesian methods in comparison with the classical methods, such as the ML, Firth’s, and exact methods using a simulation study. We also apply these methods to a real data set.Results: Our simulation results indicate that the bias of the OR from the ML, Firth’s, and exact methods is considerable. Furthermore, the Bayesian methods with hyper-g prior modeling of the prior covariance matrix for regression coefficients reduced the bias under the null hypothesis, whereas the Bayesian methods with log F-type priors reduced the bias under the alternative hypothesis.Conclusion: The Bayesian methods using log F-type priors and hyper-g prior are superior to the ML, Firth’s, and exact methods when fitting logistic models to sparse data sets. The choice of a preferable method depends on the null and alternative hypothesis. Sensitivity analysis is important to understand the robustness of the results in sparse data analysis.

7 August 2019 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
SSSatoki Shichijo
Satoki Shichijo
YTYoji Takeuchi
Yoji Takeuchi
MKMasanori Kitamura
Masanori Kitamura
MKMitsuhiro Kono
Mitsuhiro Kono
YSYusaku Shimamoto
Yusaku Shimamoto
RIRyu Ishihara
Ryu Ishihara

31 August 2021 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
Kota KatanodaKota Katanoda
Kota Katanoda
YIYuri Ito
Yuri Ito
TSTomotaka Sobue
Tomotaka Sobue
While the age-standardized mortality rate in Japan is decreasing for all cancers as a whole, this is not the case for some major site-specific cancers. We descriptively compared trends in all-cancer and site-specific cancer mortality in Japan and selected countries. Data on age-standardized cancer mortality rates in six countries (Japan, the USA, the UK, Canada, Australia and the Republic of Korea) in 1980–2016 were obtained from the World Health Organization mortality database. While stomach and liver cancer mortality rates in Japan and Korea were initially much higher than those in non-Asian countries, they have rapidly decreased over the long term. By contrast, colorectal, pancreatic and cervical cancer mortality rates in Japan, which were initially lower than those in other countries, have increased such that they are now similar or higher than the rates in non-Asian countries. For male lung cancer, Japan’s initially lower mortality rate is now comparable to that in non-Asian countries as a result of slower decline. Meanwhile, the mortality rate of female breast cancer in Japan and Korea has increased and is nearing the rates observed in non-Asian countries, which by contrast have shown a steady decrease. Thus, while Japan has been successful in reducing the burden of stomach and liver cancers, it is falling behind in reducing the mortality rate of screening-related cancers such as colorectal, female breast and cervical cancers. Control measures for these cancers need to be strengthened.

5 February 2021 in Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
TATatsuhiko Anzai
Tatsuhiko Anzai
KFKeisuke Fukui
Keisuke Fukui
TITsubasa Ito
Tsubasa Ito
YIYuri Ito
Yuri Ito
KTKunihiko Takahashi
Kunihiko Takahashi
Background: Suicide amidst the coronavirus disease (COVID-19) pandemic is an important issue. In Japan, the number of suicides in April 2020 decreased by nearly 20% from that in 2019. To assess the impact of an infectious disease pandemic, excess mortality is often discussed. Our main purpose was evaluating excess mortality from suicide in Japan during the early pandemic period.Methods: We used data on suicides collected by the National Police Agency of Japan until June 2020. We estimated excess mortality during the early pandemic period (March–June 2020) using a time-series model of the number of suicides before the pandemic. A quasi-Poisson model was employed for the estimation. We evaluated excess mortalities by the categories of age and sex, and prefectures.Results: No significant excess mortality was observed throughout the early pandemic; instead, a downward trend in the number of suicides for both sexes was noted. For males, negative values of excess mortalities below the lower bound of the 95% prediction interval were observed in April and May. All numbers of females during the period were included in the interval, and the excess mortalities in June were positive and higher than those in April and May. In Tokyo, the number of suicides was below the lower bound throughout the period.Conclusion: Our results suggest that various changes such as communication, and social conditions amid the early COVID-19 pandemic induced a decrease in suicides in Japan. However, continuous monitoring is needed to evaluate the long-term effects of the pandemic on suicides.